Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Cholesterol Screening Market by End Users (Physicians/Providers, Hospitals, Managed Care Organizations (MCOs), Government Agencies, Accountable Care Organizations (ACOs), Integrated Delivery Networks (IDNs)): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03381

Pages: NA

Charts: NA

Tables: NA

The elevated levels of cholesterol create health threats such as sharp risk of stroke & heart diseases and account for a large number of deaths. Cholesterol screening services allow early detection of the problems related to high cholesterol levels, avoiding complications and increasing the survival chances of patients.

The major factors that fuel the market growth include increase in incidence of cardiovascular diseases, sedentary lifestyle, rise in geriatric population offering a large patient pool, and government initiatives for better healthcare services. Furthermore, increase in healthcare expenditure and rise in public awareness about the cardiovascular disease, its causes, treatment, and prevention also boost the growth of the market. However, swift growth in self-testing devices and the advent of noninvasive cholesterol testing approaches hamper the growth of the market.

The global cholesterol screening market is segmented on the basis of end users and region. On the basis of end-users, it is divided into Physicians/Providers, Hospitals, Managed Care Organizations (MCOs), Government Agencies, Accountable Care Organizations (ACOs), and Integrated Delivery Networks (IDNs). By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key companies profiled in this report include ACM Medical Laboratory, Clinical Reference Laboratory, Inc., Laboratory Corporation of America Holdings, Eurofins Scientific, Quest Diagnostics Incorporated, SYNLAB International GmbH, Fresenius Medical Care Holdings, Inc.

Key Benefits

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It presents a quantitative analysis to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the market by type assists in understanding the regional trends.
  • Key players and their strategies are analyzed to understand the competitive outlook of the market.

 Key Market Segments

  • By End Users
    • Physicians/Providers
    • Hospitals
    • Managed Care Organizations (MCOs)
    • Government Agencies
    • Accountable Care Organizations (ACOs)
    • Integrated Delivery Networks (IDNs)
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Quest Diagnostics Incorporated
  • SYNLAB International GmbH
  • Fresenius Medical Care Holdings, Inc.
  • Clinical Reference Laboratory, Inc.
  • Unilabs
  • Bio-Reference Laboratories Inc.
  • ACM Medical Laboratory
  • Laboratory Corporation of America Holdings
  • Spectra Laboratories Inc.
  • Eurofins Scientific

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: CHOLESTEROL SCREENING MARKET, BY END USERS

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By End Users

    • 4.2. Physicians/Providers

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Hospitals

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Managed Care Organizations (MCOs)

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Government Agencies

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Accountable Care Organizations (ACOs)

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Integrated Delivery Networks (IDNs)

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

  • CHAPTER 5: CHOLESTEROL SCREENING MARKET, BY REGION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Region

    • 5.2. North America

      • 5.2.1. Key Market Trends and Opportunities

      • 5.2.2. Market Size and Forecast, By End Users

      • 5.2.3. Market Size and Forecast, By Country

      • 5.2.4. U.S. Cholesterol Screening Market

        • 5.2.4.1. Market Size and Forecast, By End Users

      • 5.2.5. Canada Cholesterol Screening Market

        • 5.2.5.1. Market Size and Forecast, By End Users

      • 5.2.6. Mexico Cholesterol Screening Market

        • 5.2.6.1. Market Size and Forecast, By End Users

    • 5.3. Europe

      • 5.3.1. Key Market Trends and Opportunities

      • 5.3.2. Market Size and Forecast, By End Users

      • 5.3.3. Market Size and Forecast, By Country

      • 5.3.4. France Cholesterol Screening Market

        • 5.3.4.1. Market Size and Forecast, By End Users

      • 5.3.5. Germany Cholesterol Screening Market

        • 5.3.5.1. Market Size and Forecast, By End Users

      • 5.3.6. Italy Cholesterol Screening Market

        • 5.3.6.1. Market Size and Forecast, By End Users

      • 5.3.7. Spain Cholesterol Screening Market

        • 5.3.7.1. Market Size and Forecast, By End Users

      • 5.3.8. UK Cholesterol Screening Market

        • 5.3.8.1. Market Size and Forecast, By End Users

      • 5.3.9. Russia Cholesterol Screening Market

        • 5.3.9.1. Market Size and Forecast, By End Users

      • 5.3.10. Rest Of Europe Cholesterol Screening Market

        • 5.3.10.1. Market Size and Forecast, By End Users

    • 5.4. Asia-Pacific

      • 5.4.1. Key Market Trends and Opportunities

      • 5.4.2. Market Size and Forecast, By End Users

      • 5.4.3. Market Size and Forecast, By Country

      • 5.4.4. China Cholesterol Screening Market

        • 5.4.4.1. Market Size and Forecast, By End Users

      • 5.4.5. Japan Cholesterol Screening Market

        • 5.4.5.1. Market Size and Forecast, By End Users

      • 5.4.6. India Cholesterol Screening Market

        • 5.4.6.1. Market Size and Forecast, By End Users

      • 5.4.7. South Korea Cholesterol Screening Market

        • 5.4.7.1. Market Size and Forecast, By End Users

      • 5.4.8. Australia Cholesterol Screening Market

        • 5.4.8.1. Market Size and Forecast, By End Users

      • 5.4.9. Thailand Cholesterol Screening Market

        • 5.4.9.1. Market Size and Forecast, By End Users

      • 5.4.10. Malaysia Cholesterol Screening Market

        • 5.4.10.1. Market Size and Forecast, By End Users

      • 5.4.11. Indonesia Cholesterol Screening Market

        • 5.4.11.1. Market Size and Forecast, By End Users

      • 5.4.12. Rest of Asia Pacific Cholesterol Screening Market

        • 5.4.12.1. Market Size and Forecast, By End Users

    • 5.5. LAMEA

      • 5.5.1. Key Market Trends and Opportunities

      • 5.5.2. Market Size and Forecast, By End Users

      • 5.5.3. Market Size and Forecast, By Country

      • 5.5.4. Brazil Cholesterol Screening Market

        • 5.5.4.1. Market Size and Forecast, By End Users

      • 5.5.5. South Africa Cholesterol Screening Market

        • 5.5.5.1. Market Size and Forecast, By End Users

      • 5.5.6. Saudi Arabia Cholesterol Screening Market

        • 5.5.6.1. Market Size and Forecast, By End Users

      • 5.5.7. UAE Cholesterol Screening Market

        • 5.5.7.1. Market Size and Forecast, By End Users

      • 5.5.8. Argentina Cholesterol Screening Market

        • 5.5.8.1. Market Size and Forecast, By End Users

      • 5.5.9. Rest of LAMEA Cholesterol Screening Market

        • 5.5.9.1. Market Size and Forecast, By End Users

  • CHAPTER 6: COMPETITIVE LANDSCAPE

    • 6.1. Introduction

    • 6.2. Top Winning Strategies

    • 6.3. Product Mapping Of Top 10 Player

    • 6.4. Competitive Dashboard

    • 6.5. Competitive Heatmap

    • 6.6. Top Player Positioning, 2024

  • CHAPTER 7: COMPANY PROFILES

    • 7.1. ACM Medical Laboratory

      • 7.1.1. Company Overview

      • 7.1.2. Key Executives

      • 7.1.3. Company Snapshot

      • 7.1.4. Operating Business Segments

      • 7.1.5. Product Portfolio

      • 7.1.6. Business Performance

      • 7.1.7. Key Strategic Moves and Developments

    • 7.2. Clinical Reference Laboratory, Inc.

      • 7.2.1. Company Overview

      • 7.2.2. Key Executives

      • 7.2.3. Company Snapshot

      • 7.2.4. Operating Business Segments

      • 7.2.5. Product Portfolio

      • 7.2.6. Business Performance

      • 7.2.7. Key Strategic Moves and Developments

    • 7.3. Laboratory Corporation Of America Holdings

      • 7.3.1. Company Overview

      • 7.3.2. Key Executives

      • 7.3.3. Company Snapshot

      • 7.3.4. Operating Business Segments

      • 7.3.5. Product Portfolio

      • 7.3.6. Business Performance

      • 7.3.7. Key Strategic Moves and Developments

    • 7.4. Eurofins Scientific

      • 7.4.1. Company Overview

      • 7.4.2. Key Executives

      • 7.4.3. Company Snapshot

      • 7.4.4. Operating Business Segments

      • 7.4.5. Product Portfolio

      • 7.4.6. Business Performance

      • 7.4.7. Key Strategic Moves and Developments

    • 7.5. Quest Diagnostics Incorporated

      • 7.5.1. Company Overview

      • 7.5.2. Key Executives

      • 7.5.3. Company Snapshot

      • 7.5.4. Operating Business Segments

      • 7.5.5. Product Portfolio

      • 7.5.6. Business Performance

      • 7.5.7. Key Strategic Moves and Developments

    • 7.6. SYNLAB International GmbH

      • 7.6.1. Company Overview

      • 7.6.2. Key Executives

      • 7.6.3. Company Snapshot

      • 7.6.4. Operating Business Segments

      • 7.6.5. Product Portfolio

      • 7.6.6. Business Performance

      • 7.6.7. Key Strategic Moves and Developments

    • 7.7. Fresenius Medical Care Holdings, Inc.

      • 7.7.1. Company Overview

      • 7.7.2. Key Executives

      • 7.7.3. Company Snapshot

      • 7.7.4. Operating Business Segments

      • 7.7.5. Product Portfolio

      • 7.7.6. Business Performance

      • 7.7.7. Key Strategic Moves and Developments

    • 7.8. Spectra Laboratories Inc.

      • 7.8.1. Company Overview

      • 7.8.2. Key Executives

      • 7.8.3. Company Snapshot

      • 7.8.4. Operating Business Segments

      • 7.8.5. Product Portfolio

      • 7.8.6. Business Performance

      • 7.8.7. Key Strategic Moves and Developments

    • 7.9. Unilabs

      • 7.9.1. Company Overview

      • 7.9.2. Key Executives

      • 7.9.3. Company Snapshot

      • 7.9.4. Operating Business Segments

      • 7.9.5. Product Portfolio

      • 7.9.6. Business Performance

      • 7.9.7. Key Strategic Moves and Developments

    • 7.10. Bio-Reference Laboratories Inc.

      • 7.10.1. Company Overview

      • 7.10.2. Key Executives

      • 7.10.3. Company Snapshot

      • 7.10.4. Operating Business Segments

      • 7.10.5. Product Portfolio

      • 7.10.6. Business Performance

      • 7.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL CHOLESTEROL SCREENING MARKET, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL CHOLESTEROL SCREENING MARKET FOR PHYSICIANS/PROVIDERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL CHOLESTEROL SCREENING MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL CHOLESTEROL SCREENING MARKET FOR MANAGED CARE ORGANIZATIONS (MCOS), BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL CHOLESTEROL SCREENING MARKET FOR GOVERNMENT AGENCIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL CHOLESTEROL SCREENING MARKET FOR ACCOUNTABLE CARE ORGANIZATIONS (ACOS), BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL CHOLESTEROL SCREENING MARKET FOR INTEGRATED DELIVERY NETWORKS (IDNS), BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL CHOLESTEROL SCREENING MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. NORTH AMERICA CHOLESTEROL SCREENING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. NORTH AMERICA CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 11. U.S. CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 12. CANADA CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 13. MEXICO CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 14. EUROPE CHOLESTEROL SCREENING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. EUROPE CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 16. FRANCE CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 17. GERMANY CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 18. ITALY CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 19. SPAIN CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 20. UK CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 21. RUSSIA CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 22. REST OF EUROPE CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 23. ASIA-PACIFIC CHOLESTEROL SCREENING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 24. ASIA-PACIFIC CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 25. CHINA CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 26. JAPAN CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 27. INDIA CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 28. SOUTH KOREA CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 29. AUSTRALIA CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 30. THAILAND CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 31. MALAYSIA CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 32. INDONESIA CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 33. REST OF ASIA PACIFIC CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 34. LAMEA CHOLESTEROL SCREENING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 35. LAMEA CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 36. BRAZIL CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 37. SOUTH AFRICA CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 38. SAUDI ARABIA CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 39. UAE CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 40. ARGENTINA CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 41. REST OF LAMEA CHOLESTEROL SCREENING, BY END USERS, 2025-2033 ($MILLION)
  • TABLE 42. ACM MEDICAL LABORATORY: KEY EXECUTIVES
  • TABLE 43. ACM MEDICAL LABORATORY: COMPANY SNAPSHOT
  • TABLE 44. ACM MEDICAL LABORATORY: OPERATING SEGMENTS
  • TABLE 45. ACM MEDICAL LABORATORY: PRODUCT PORTFOLIO
  • TABLE 46. ACM MEDICAL LABORATORY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 47. CLINICAL REFERENCE LABORATORY, INC.: KEY EXECUTIVES
  • TABLE 48. CLINICAL REFERENCE LABORATORY, INC.: COMPANY SNAPSHOT
  • TABLE 49. CLINICAL REFERENCE LABORATORY, INC.: OPERATING SEGMENTS
  • TABLE 50. CLINICAL REFERENCE LABORATORY, INC.: PRODUCT PORTFOLIO
  • TABLE 51. CLINICAL REFERENCE LABORATORY, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 52. LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY EXECUTIVES
  • TABLE 53. LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
  • TABLE 54. LABORATORY CORPORATION OF AMERICA HOLDINGS: OPERATING SEGMENTS
  • TABLE 55. LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
  • TABLE 56. LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 57. EUROFINS SCIENTIFIC: KEY EXECUTIVES
  • TABLE 58. EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 59. EUROFINS SCIENTIFIC: OPERATING SEGMENTS
  • TABLE 60. EUROFINS SCIENTIFIC: PRODUCT PORTFOLIO
  • TABLE 61. EUROFINS SCIENTIFIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 62. QUEST DIAGNOSTICS INCORPORATED: KEY EXECUTIVES
  • TABLE 63. QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT
  • TABLE 64. QUEST DIAGNOSTICS INCORPORATED: OPERATING SEGMENTS
  • TABLE 65. QUEST DIAGNOSTICS INCORPORATED: PRODUCT PORTFOLIO
  • TABLE 66. QUEST DIAGNOSTICS INCORPORATED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 67. SYNLAB INTERNATIONAL GMBH: KEY EXECUTIVES
  • TABLE 68. SYNLAB INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • TABLE 69. SYNLAB INTERNATIONAL GMBH: OPERATING SEGMENTS
  • TABLE 70. SYNLAB INTERNATIONAL GMBH: PRODUCT PORTFOLIO
  • TABLE 71. SYNLAB INTERNATIONAL GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 72. FRESENIUS MEDICAL CARE HOLDINGS, INC.: KEY EXECUTIVES
  • TABLE 73. FRESENIUS MEDICAL CARE HOLDINGS, INC.: COMPANY SNAPSHOT
  • TABLE 74. FRESENIUS MEDICAL CARE HOLDINGS, INC.: OPERATING SEGMENTS
  • TABLE 75. FRESENIUS MEDICAL CARE HOLDINGS, INC.: PRODUCT PORTFOLIO
  • TABLE 76. FRESENIUS MEDICAL CARE HOLDINGS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 77. SPECTRA LABORATORIES INC.: KEY EXECUTIVES
  • TABLE 78. SPECTRA LABORATORIES INC.: COMPANY SNAPSHOT
  • TABLE 79. SPECTRA LABORATORIES INC.: OPERATING SEGMENTS
  • TABLE 80. SPECTRA LABORATORIES INC.: PRODUCT PORTFOLIO
  • TABLE 81. SPECTRA LABORATORIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 82. UNILABS: KEY EXECUTIVES
  • TABLE 83. UNILABS: COMPANY SNAPSHOT
  • TABLE 84. UNILABS: OPERATING SEGMENTS
  • TABLE 85. UNILABS: PRODUCT PORTFOLIO
  • TABLE 86. UNILABS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 87. BIO-REFERENCE LABORATORIES INC.: KEY EXECUTIVES
  • TABLE 88. BIO-REFERENCE LABORATORIES INC.: COMPANY SNAPSHOT
  • TABLE 89. BIO-REFERENCE LABORATORIES INC.: OPERATING SEGMENTS
  • TABLE 90. BIO-REFERENCE LABORATORIES INC.: PRODUCT PORTFOLIO
  • TABLE 91. BIO-REFERENCE LABORATORIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL CHOLESTEROL SCREENING MARKET SEGMENTATION
  • FIGURE 2. GLOBAL CHOLESTEROL SCREENING MARKET
  • FIGURE 3. SEGMENTATION CHOLESTEROL SCREENING MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN CHOLESTEROL SCREENING MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCHOLESTEROL SCREENING MARKET
  • FIGURE 11. CHOLESTEROL SCREENING MARKET SEGMENTATION, BY BY END USERS
  • FIGURE 12. CHOLESTEROL SCREENING MARKET FOR PHYSICIANS/PROVIDERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. CHOLESTEROL SCREENING MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. CHOLESTEROL SCREENING MARKET FOR MANAGED CARE ORGANIZATIONS (MCOS), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. CHOLESTEROL SCREENING MARKET FOR GOVERNMENT AGENCIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. CHOLESTEROL SCREENING MARKET FOR ACCOUNTABLE CARE ORGANIZATIONS (ACOS), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. CHOLESTEROL SCREENING MARKET FOR INTEGRATED DELIVERY NETWORKS (IDNS), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 19. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 20. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 21. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 22. COMPETITIVE DASHBOARD
  • FIGURE 23. COMPETITIVE HEATMAP: CHOLESTEROL SCREENING MARKET
  • FIGURE 24. TOP PLAYER POSITIONING, 2024
  • FIGURE 25. ACM MEDICAL LABORATORY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 26. ACM MEDICAL LABORATORY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 27. ACM MEDICAL LABORATORY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 28. CLINICAL REFERENCE LABORATORY, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 29. CLINICAL REFERENCE LABORATORY, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 30. CLINICAL REFERENCE LABORATORY, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 31. LABORATORY CORPORATION OF AMERICA HOLDINGS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. LABORATORY CORPORATION OF AMERICA HOLDINGS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. LABORATORY CORPORATION OF AMERICA HOLDINGS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. EUROFINS SCIENTIFIC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. EUROFINS SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. EUROFINS SCIENTIFIC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. QUEST DIAGNOSTICS INCORPORATED: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. QUEST DIAGNOSTICS INCORPORATED: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. QUEST DIAGNOSTICS INCORPORATED: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. SYNLAB INTERNATIONAL GMBH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. SYNLAB INTERNATIONAL GMBH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. SYNLAB INTERNATIONAL GMBH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. FRESENIUS MEDICAL CARE HOLDINGS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. FRESENIUS MEDICAL CARE HOLDINGS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. FRESENIUS MEDICAL CARE HOLDINGS, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. SPECTRA LABORATORIES INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. SPECTRA LABORATORIES INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. SPECTRA LABORATORIES INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. UNILABS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. UNILABS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. UNILABS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. BIO-REFERENCE LABORATORIES INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. BIO-REFERENCE LABORATORIES INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. BIO-REFERENCE LABORATORIES INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Cholesterol Screening Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved